Cargando…

A Randomized, Double-Blind, Placebo-Controlled Investigation of Selenium Supplementation in Women at Elevated Risk for Breast Cancer: Lessons for Re-Emergent Interest in Selenium and Cancer

Damage to cellular macromolecules such as DNA and lipid, induced via reactive oxygen species, and indicators of cell proliferation potential such as insulin-like growth factor (IGF) metabolic status are intermediate biomarkers of breast cancer risk. Based on reports that selenium status can affect t...

Descripción completa

Detalles Bibliográficos
Autores principales: Thompson, Henry J., Sedlacek, Scot M., Fitzgerald, Vanessa K., Wolfe, Pamela, McGinley, John N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9855926/
https://www.ncbi.nlm.nih.gov/pubmed/36672557
http://dx.doi.org/10.3390/biomedicines11010049
_version_ 1784873495559143424
author Thompson, Henry J.
Sedlacek, Scot M.
Fitzgerald, Vanessa K.
Wolfe, Pamela
McGinley, John N.
author_facet Thompson, Henry J.
Sedlacek, Scot M.
Fitzgerald, Vanessa K.
Wolfe, Pamela
McGinley, John N.
author_sort Thompson, Henry J.
collection PubMed
description Damage to cellular macromolecules such as DNA and lipid, induced via reactive oxygen species, and indicators of cell proliferation potential such as insulin-like growth factor (IGF) metabolic status are intermediate biomarkers of breast cancer risk. Based on reports that selenium status can affect these markers, a randomized, placebo-controlled, double-blind experiment was conducted to investigate the potential of selenium supplementation to modulate breast cancer risk. Using a placebo tablet or a tablet containing 200 μg selenium provided as high-selenium yeast daily for one year, concentrations of the biomarkers in blood or urine were assessed at baseline and after 6 and 12 months of intervention. The selenium intervention used in this study is presumed to mediate its effect via the induction of glutathione peroxidase activity and the consequential impact of the active form of this protein on oxidative damage. We found no evidence to support this hypothesis or to indicate that systemic IGF metabolic status was affected. Critical knowledge gaps must be addressed for the resurgence of interest in selenium and cancer to garner clinical relevance. Those knowledge gaps include the identification of a specific, high-affinity selenium metabolite and the cellular target(s) to which it binds, and the demonstration that the cellular determinant that the selenium metabolite binds plays a critical role in the initiation, promotion, or progression of a specific type of cancer.
format Online
Article
Text
id pubmed-9855926
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98559262023-01-21 A Randomized, Double-Blind, Placebo-Controlled Investigation of Selenium Supplementation in Women at Elevated Risk for Breast Cancer: Lessons for Re-Emergent Interest in Selenium and Cancer Thompson, Henry J. Sedlacek, Scot M. Fitzgerald, Vanessa K. Wolfe, Pamela McGinley, John N. Biomedicines Article Damage to cellular macromolecules such as DNA and lipid, induced via reactive oxygen species, and indicators of cell proliferation potential such as insulin-like growth factor (IGF) metabolic status are intermediate biomarkers of breast cancer risk. Based on reports that selenium status can affect these markers, a randomized, placebo-controlled, double-blind experiment was conducted to investigate the potential of selenium supplementation to modulate breast cancer risk. Using a placebo tablet or a tablet containing 200 μg selenium provided as high-selenium yeast daily for one year, concentrations of the biomarkers in blood or urine were assessed at baseline and after 6 and 12 months of intervention. The selenium intervention used in this study is presumed to mediate its effect via the induction of glutathione peroxidase activity and the consequential impact of the active form of this protein on oxidative damage. We found no evidence to support this hypothesis or to indicate that systemic IGF metabolic status was affected. Critical knowledge gaps must be addressed for the resurgence of interest in selenium and cancer to garner clinical relevance. Those knowledge gaps include the identification of a specific, high-affinity selenium metabolite and the cellular target(s) to which it binds, and the demonstration that the cellular determinant that the selenium metabolite binds plays a critical role in the initiation, promotion, or progression of a specific type of cancer. MDPI 2022-12-25 /pmc/articles/PMC9855926/ /pubmed/36672557 http://dx.doi.org/10.3390/biomedicines11010049 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Thompson, Henry J.
Sedlacek, Scot M.
Fitzgerald, Vanessa K.
Wolfe, Pamela
McGinley, John N.
A Randomized, Double-Blind, Placebo-Controlled Investigation of Selenium Supplementation in Women at Elevated Risk for Breast Cancer: Lessons for Re-Emergent Interest in Selenium and Cancer
title A Randomized, Double-Blind, Placebo-Controlled Investigation of Selenium Supplementation in Women at Elevated Risk for Breast Cancer: Lessons for Re-Emergent Interest in Selenium and Cancer
title_full A Randomized, Double-Blind, Placebo-Controlled Investigation of Selenium Supplementation in Women at Elevated Risk for Breast Cancer: Lessons for Re-Emergent Interest in Selenium and Cancer
title_fullStr A Randomized, Double-Blind, Placebo-Controlled Investigation of Selenium Supplementation in Women at Elevated Risk for Breast Cancer: Lessons for Re-Emergent Interest in Selenium and Cancer
title_full_unstemmed A Randomized, Double-Blind, Placebo-Controlled Investigation of Selenium Supplementation in Women at Elevated Risk for Breast Cancer: Lessons for Re-Emergent Interest in Selenium and Cancer
title_short A Randomized, Double-Blind, Placebo-Controlled Investigation of Selenium Supplementation in Women at Elevated Risk for Breast Cancer: Lessons for Re-Emergent Interest in Selenium and Cancer
title_sort randomized, double-blind, placebo-controlled investigation of selenium supplementation in women at elevated risk for breast cancer: lessons for re-emergent interest in selenium and cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9855926/
https://www.ncbi.nlm.nih.gov/pubmed/36672557
http://dx.doi.org/10.3390/biomedicines11010049
work_keys_str_mv AT thompsonhenryj arandomizeddoubleblindplacebocontrolledinvestigationofseleniumsupplementationinwomenatelevatedriskforbreastcancerlessonsforreemergentinterestinseleniumandcancer
AT sedlacekscotm arandomizeddoubleblindplacebocontrolledinvestigationofseleniumsupplementationinwomenatelevatedriskforbreastcancerlessonsforreemergentinterestinseleniumandcancer
AT fitzgeraldvanessak arandomizeddoubleblindplacebocontrolledinvestigationofseleniumsupplementationinwomenatelevatedriskforbreastcancerlessonsforreemergentinterestinseleniumandcancer
AT wolfepamela arandomizeddoubleblindplacebocontrolledinvestigationofseleniumsupplementationinwomenatelevatedriskforbreastcancerlessonsforreemergentinterestinseleniumandcancer
AT mcginleyjohnn arandomizeddoubleblindplacebocontrolledinvestigationofseleniumsupplementationinwomenatelevatedriskforbreastcancerlessonsforreemergentinterestinseleniumandcancer
AT thompsonhenryj randomizeddoubleblindplacebocontrolledinvestigationofseleniumsupplementationinwomenatelevatedriskforbreastcancerlessonsforreemergentinterestinseleniumandcancer
AT sedlacekscotm randomizeddoubleblindplacebocontrolledinvestigationofseleniumsupplementationinwomenatelevatedriskforbreastcancerlessonsforreemergentinterestinseleniumandcancer
AT fitzgeraldvanessak randomizeddoubleblindplacebocontrolledinvestigationofseleniumsupplementationinwomenatelevatedriskforbreastcancerlessonsforreemergentinterestinseleniumandcancer
AT wolfepamela randomizeddoubleblindplacebocontrolledinvestigationofseleniumsupplementationinwomenatelevatedriskforbreastcancerlessonsforreemergentinterestinseleniumandcancer
AT mcginleyjohnn randomizeddoubleblindplacebocontrolledinvestigationofseleniumsupplementationinwomenatelevatedriskforbreastcancerlessonsforreemergentinterestinseleniumandcancer